Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-13-056694)

Filing Details

Accession Number:: 0001209191-13-056694
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-12-12 17:48:42
Reporting Period:: 2013-12-12

Filing Date:: 2013-12-12
Accepted Time:: 2013-12-12 17:48:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557290	A Stuart Arbuckle	C/O Vertex Pharmaceuticals Incorporated 130 Waverly St. Cambridge, MA 02139	Evp\Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-12-12	3,021	$65.47	36,718	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	140	Indirect	401(k)

Footnotes

Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $65.47 (range $65.06 to $65.92).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.